Patents by Inventor Marilena KAMPA

Marilena KAMPA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS USEFUL AS ANTI-VIRAL AGENTS
    Publication number: 20230101903
    Abstract: The present invention relates to compounds of Formula (I) and compositions containing one or more compounds of Formula (I). The compounds and compositions are useful as anti-viral agents and may be used in the treatment or prevention of diseases caused by ribonucleic acid (RNA) viruses.
    Type: Application
    Filed: February 11, 2021
    Publication date: March 30, 2023
    Inventors: Elias CASTANAS, George SOURVINOS, Marilena KAMPA, Christos LIONIS, Stergios PIRINTSOS, Athanasios PANAGIOTOPOULOS, Melpomeni TSELIOU
  • ESTROGEN RECEPTOR ALPHA POLYPEPTIDE SEQUENCE, DIAGNOSTIC AND THERAPEUTIC APPLICATIONS THEREOF
    Publication number: 20130224285
    Abstract: The present invention presents new insights in the mechanism of action of the estrogen receptor alpha in breast cancer cells and provides means and tools for modulating said mechanisms of action, thereby influencing the proliferation of estrogen-positive cells such as cancer cells.
    Type: Application
    Filed: October 13, 2011
    Publication date: August 29, 2013
    Applicants: Universite Libre de Buxelles, UNIVERSITE PIERRE ET MARIE CURIE - UPMC, CNRS, UNIVERSITY OF CRETE - SCHOOL OF MEDICINE
    Inventors: Dominique Gallo, Guy LeClercq, Iman Haddad, Joelle Vinh, Elias Castanas, Marilena Kampa, Vasiliki Pelekanou, Yves Jacquot
  • POTENTIATION OF ERYTHROPOIETIN (EPO) ACTION BY MEMBRANE STEROID RECEPTOR AGONISTS
    Publication number: 20100086542
    Abstract: The present invention relates to the use of membrane steroid receptor agonists as potentiators of the action of erythropoietin (EPO). The present invention also relates to the combined use of membrane steroid receptor agonists and erythropoietin to control apoptosis, proliferation, differentiation, migration and regeneration of cells, in different organs and tissues. Compositions comprising (i) a membrane steroid receptor agonist and (ii) erythropoietin are also provided, as are kits comprising (i) a membrane steroid receptor agonist and (ii) erythropoietin.
    Type: Application
    Filed: November 27, 2007
    Publication date: April 8, 2010
    Applicant: BIONATURE E.A. LTD.
    Inventors: Elias CASTANAS, Marilena KAMPA, Vassiliki PELEKANOU